Gilead Sciences (GILD) is Downgraded by Leerink Partners to Mkt Perform, Lowers Price Target to $ 94

Gilead Sciences (GILD) was Downgraded by Leerink Partners to ” Mkt Perform” while Lowering the Price Target of the company shares to $ 94 from a previous price target of $112 . Earlier the firm had a rating of “Outperform ” on the company shares. Leerink Partners advised their investors in a research report released on Sep 27, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Gilead Sciences closed down -0.18 points or -0.22% at $81.52 with 82,13,760 shares getting traded on Thursday. Post opening the session at $81.97, the shares hit an intraday low of $80.9 and an intraday high of $82 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on Sep 26, 2016, Gregg H Alton (EVP Comm&Acs ALA, Corp&Med Aff) sold 5,000 shares at $81.84 per share price. According to the SEC, on Sep 8, 2016, John F Milligan (President and CEO) sold 70,000 shares at $77.74 per share price. On Sep 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $77.82 per share price, according to the Form-4 filing with the securities and exchange commission.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Gilead Sciences

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.